http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2022115664-A2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b0415d6923e2f80c6c8872becb568967 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-167 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-15 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4045 |
| filingDate | 2021-11-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c3fb1fee2f068674e006a794e8e6eb72 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0eaed019d0a45be5a498f20432745ffd |
| publicationDate | 2022-06-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | WO-2022115664-A2 |
| titleOfInvention | Methods for treating cancer using combinations of epigenetic therapies and radioconjugate targeting agents |
| abstract | The invention provides methods for treating a cancer, such as acute myeloid leukemia, in a mammalian subject that include administering to the subject (i) an epigenetic drug such as one or both an HD AC inhibitor and an LSD1/KDM1 A inhibitor, and (ii) a radioisotope-labeled agent that targets cancer cells in the subject, wherein the amounts of the epigenetic drug(s) and radiolabeled agent, when administered in conjunction with one another, are therapeutically effective. |
| priorityDate | 2020-11-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 730.